Skip to main content

Table 1 Cohort description

From: SAR1a promoter polymorphisms are not associated with fetal hemoglobin in patients with sickle cell disease from Cameroon

Variables   Mean ± SD Value range Number of observations
Age (years)   17.9 ± 10.6 5–57 484
Haematological indices RBC (1012/l) 2.8 ± 0.7 1.2–5.5 484
Hb (g/dl) 7.8 ± 1.6 4.0–13.5 484
MCV(fl) 84.6 ± 10.0 61–112 484
MCHC (g/dl) 34.2 ± 3.8 22.3–54.0 484
WBC (109/l) 14.7 ± 6.4 3.5–48.8 484
Lymphocytes (109/l) 6.1 ± 3.3 0.87–20.4 484
Monocytes (109/l) 1.7 ± 1.4 0.1–10.9 484
Platelets (109/l) 371.5 ± 131.6 108–827 484
HbA2 (%) 3.6 ± 2.1 0.1–18.2 484
HbF (%) 10.1 ± 8.5 0–37.4 484
Clinical events Vaso-occlusive crisis (No./year) 2.8 ± 3.3 0–40 484
Consultations (No./year) 3.0 ± 3.9 0–24 484
Hospitalisation (No./year) 1.4 ± 2.5 0–30 484
Overt stroke 4.5%   22/484
3.7del α-globin gene genotypes αα/αα 62.9%   304/484a
αα/α3.7 28.5%   138/484a
α3.7/α3.7 8.6%   42/484a
β-globin gene haplotypes Benin/Benin 50.2%   243/484a
Benin/Cameroon 21.7%   105/484a
Benin/Atypical 4.1%   20/484a
Cameroon/Cameroon 4.1%   20/484a
  1. RBC red blood cells, Hb hemoglobin, MCV mean corpuscular volume, MCHC mean corpuscular haemoglobin concentration, WBC white blood cells, HbA2 hemoglobin α2, HbF hemoglobin F
  2. aNumber of individuals and not alleles